More about D.C. Brewer's Ball and the CFF
WHAT: The 9th Annual Brewer's Ball Presnted by AirWatch, is a unique beer-tasting event is on March 2, 2013. A popular annual tradition, Brewer’s Ball will offer guests the opportunity to sample a variety of handcrafted microbrews from more than a dozen of the region’s best microbreweries and brewpubs, while also enjoying the cuisine of several popular restaurants. The evening will feature live entertainment and one of the region’s most memorable silent auctions. It will be an exciting opportunity to invite your family, friends and clients to enjoy the hand crafted brews and delicious restaurant samplings from the region, meet and mingle with other area sponsors and elite young professionals. Net proceeds from this event benefit the Cystic Fibrosis Foundation and our mission to cure and control cystic fibrosis and to improve the quality of lives for those living with the disease. The Brewer’s Ball is the microbrew gala of the season!
WHEN: Saturday, March, 2, 2013
WHERE: National Building Museum, 401 F St NW, Washington D.C., 20001
ATTEND: Tickets for our event are no longer available.
DRESS CODE: Cocktail Attire
DONATE: Unable to attend but would like to make a donation? Please visit: https://www.cff.org/Chapters/metrodc/EventDonation/?idEvent=23196
WHY: Cystic Fibrosis is one of the leading genetic killers of children in the United States. The defective gene substantially impairs normal respiratory and digestive functions making the simple acts of breathing and eating a daily challenge. The median age of survival is 37.5 years – there is no cure.
January 31, 2012 marked an important milestone in our journey to find a cure for cystic fibrosis became a more realistic one with the FDA approval of Kalydeco™, a breakthrough drug that addresses the underlying cause of CF. The science behind Kalydeco has opened exciting new doors to research and development that may eventually lead to a cure. Indeed, recent results from a Phase 2 study of Kalydeco combined with another potential drug, VX-809, showed promise in people with two copies of the most common CF mutation, and further combination trials are planned. We have also expanded our research collaborations with leading pharmaceutical companies, including Vertex, Pfizer, Genzyme and Proteostasis, to accelerate the discovery of additional drugs to help everyone with CF.
Our groundbreaking progress is a testament to the dedication of the countless patients, families, donors, volunteers and staff who believed that we could do what many thought was impossible: attack this disease at its root.
CONTACT: For more information contact Erin Leahey at the Cystic Fibrosis Foundation Metropolitan Washington, D.C. Chapter at (301) 657-8444 x 201 or via email at eleahey@cff.org
